Dapiglutide, targeting both GLP-1 and GLP-2 receptors simultaneously, produced a 2.1% weight reduction over 12 weeks in 54 adults with obesity, though this fell short of statistical significance (p=0.076). The dual mechanism combines GLP-1's appetite suppression with GLP-2's gut barrier protection and anti-inflammatory effects—a theoretically promising approach for sustainable weight management. The modest weight loss aligns with early-phase trials of other GLP-receptor agonists before dose optimization. What's notable is the excellent tolerability profile: zero discontinuations due to adverse events and minimal dropout rates across all groups, contrasting favorably with existing GLP-1 therapies that often cause significant gastrointestinal distress. This suggests the GLP-2 component may indeed provide gut-protective benefits. However, the small sample size and brief duration limit interpretability. The pharmaceutical landscape for obesity is rapidly evolving, with tirzepatide and semaglutide achieving 15-20% weight reductions. For dapiglutide to compete, higher doses and longer trials are essential. This represents an incremental advance in dual-receptor targeting rather than a breakthrough, but the safety profile warrants continued investigation in larger cohorts.